|
Written by Janus
|
|
Wednesday, 16 January 2013 09:53 |
|
A growing number of insights on the biology of bacterial inclusion bodies (IBs) have revealed intriguing utilities of these protein particles. Since they combine mechanical stability and protein functionality, IBs have been already exploited in biocatalysis and explored for bottom-up topographical modification in tissue engineering. Being fully biocompatible and with tuneable bio-physical properties, IBs are currently emerging as agents for protein delivery into mammalian cells in protein-replacement cell therapies. So far, IBs formed by chaperones (heat shock protein 70, Hsp70), enzymes (catalase and dihydrofolate reductase), grow factors (leukemia inhibitory factor, LIF) and structural proteins (the cytoskeleton keratin 14) have been shown to rescue exposed cells from a spectrum of stresses and restore cell functions in absence of cytotoxicity. The natural penetrability of IBs into mammalian cells (reaching both cytoplasm and nucleus) empowers them as an unexpected platform for the controlled delivery of essentially any therapeutic polypeptide. Production of protein drugs by biopharma has been traditionally challenged by IB formation. However, a time might have arrived in which recombinant bacteria are to be engineered for the controlled packaging of therapeutic proteins as nanoparticulate materials (nanopills), for their extra- or intra-cellular release in medicine and cosmetics.
http://www.microbialcellfactories.com/content/11/1/76
|
|
Written by Janus
|
|
Wednesday, 04 July 2012 13:24 |
|
• Aquilon, The technology-based company was founded in March 2012 from technologies generated at the University of León and Autonomous University of Barcelona, based on a project conceived and led by Janus Developments.
• The investment fund SEGURANZA, promoted by the Ministry of Economy and Employment of the Junta de Castilla y León through the Agency for Innovation and Corporate Finance and managed by Clave Mayor, has committed € 1.5 million in the capital of the company, leveraged with a loan of 0.43 M € from the InnoCash program of Genoma España.
• During the next three years the company will develop vaccines and probiotics to fight against intestinal and respiratory diseases with high impact on animal productivity, mainly in the pig production sector.
• The company aims to become the natural channel of technology development and commercialization of academic technologies with potential to generate innovative products in animal health.
|
